Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2: potential implications for neurological symptoms in COVID-19, 2022, Charnley et al

Discussion in 'Long Covid research' started by Andy, Jun 13, 2022.

  1. Andy

    Andy Committee Member

    Messages:
    22,399
    Location:
    Hampshire, UK
    Abstract

    COVID-19 is primarily known as a respiratory disease caused by SARS-CoV-2. However, neurological symptoms such as memory loss, sensory confusion, severe headaches, and even stroke are reported in up to 30% of cases and can persist even after the infection is over (long COVID). These neurological symptoms are thought to be produced by the virus infecting the central nervous system, however we don’t understand the molecular mechanisms triggering them. The neurological effects of COVID-19 share similarities to neurodegenerative diseases in which the presence of cytotoxic aggregated amyloid protein or peptides is a common feature. Following the hypothesis that some neurological symptoms of COVID-19 may also follow an amyloid etiology we identified two peptides from the SARS-CoV-2 proteome that self-assemble into amyloid assemblies. Furthermore, these amyloids were shown to be highly toxic to neuronal cells. We suggest that cytotoxic aggregates of SARS-CoV-2 proteins may trigger neurological symptoms in COVID-19.

    Open access, https://www.nature.com/articles/s41467-022-30932-1
     
  2. rvallee

    rvallee Senior Member (Voting Rights)

    Messages:
    13,002
    Location:
    Canada
    Alzheimer's research has mostly focused on amyloid for the last several decades. I really hope this means they have a leg up on this and can take it from here. Even if it's to debunk this. Surely decades and billions in research can be somewhat leveraged here without having to redo all the groundwork from scratch.

    Surely...
     
    mango, DokaGirl, Hutan and 2 others like this.
  3. mango

    mango Senior Member (Voting Rights)

    Messages:
    2,655
    Peter Trewhitt likes this.

Share This Page